原发性硬化性胆管炎的人群流行病学、自然史与结局:基于人群研究的系统综述
该系统综述纳入17项基于人群的研究,量化全球原发性硬化性胆管炎(PSC)的发病率与患病率,并汇总肝移植、胆管癌及死亡风险。北欧和北美发病率最高(芬兰1.58/10万、挪威1.3/10万、明尼苏达1.47/10万),地中海盆地最低(意大利0.1/10万)。北美和北欧发病率和患病率呈上升趋势,中位无移植生存9.7至20.6年,标准化死亡比2.5至4.2,胆管癌标准化发病率235至398。
要点
- PSC发病率以北欧和北美最高,意大利最低,全球分布不均。
- 北美和北欧PSC发病率和患病率随时间上升。
- PSC患者死亡风险和胆管癌风险显著高于一般人群。
核心结论
- PSC的发病率和患病率估计值存在差异,多数研究来自北美和西欧,后者显示疾病发生呈持续上升趋势。
研究设计与样本
- 系统综述检索MEDLINE和EMBASE至2020年6月30日,纳入报告PSC发病率和/或患病率的基于人群研究,排除非原始数据、仅儿童起病(诊断年龄<16岁)或仅合并炎症性肠病的PSC研究。
- 共4922篇文献中17项研究符合纳入标准,其中16项报告发病率、14项报告患病率。
主要发现
- 最高发病率报告于北欧(芬兰1.58/10万、挪威1.3/10万)和北美(明尼苏达1.47/10万),最低见于地中海盆地(意大利0.1/10万)。
- 患病率从芬兰31.7、明尼苏达23.99,到新加坡1.33和阿拉斯加0.0不等。
- 报告时间趋势的研究中,北美和北欧4项研究观察到发病率增加,4项研究观察到患病率随时间增加。
- 9项研究报告了临床结局风险,中位无移植生存从美国9.7年到荷兰20.6年,标准化死亡比分别为2.5和4.2(对照人群)。
- 胆管癌标准化发病率从芬兰235到荷兰398。
临床怎么用
- 消化内科医生应了解PSC发病率和患病率存在显著地域差异,北欧和北美为高发区。
- 对PSC患者应关注胆管癌监测和肝移植评估,因其死亡和胆管癌风险显著升高。
局限性
- 多数研究来自北美和西欧,发展中国家数据缺乏。
- 发病率和患病率估计值存在异质性,需进一步研究病因驱动因素和疾病负担对卫生政策的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: The aim of this study was to quantify the global epidemiology of primary sclerosing cholangitis (PSC), alongside the incidence of liver transplantation, cancer, and death, through robust systematic review of population-based data. METHODS: We searched MEDLINE and EMBASE up to and including June 30, 2020 to identify population-based studies reporting the incidence and/or prevalence of PSC. Studies that did not report original data, or of exclusively pediatric-onset disease (diagnosis age <16 years) or exclusively PSC-associated with inflammatory bowel disease were excluded. RESULTS: Of 4922 published studies, 17 fulfilled inclusion criteria; 16 documenting incidence and 14 prevalence. The highest reported incidence of PSC was reported in Northern Europe (Finland, 1.58 and Norway, 1.3 per-100,000 population, respectively) and North America (Minnesota, 1.47); with the lowest being observed across the Mediterranean Basin (Italy, 0.1). Prevalence ranged from 31.7 in Finland and 23.99 in Minnesota, to 1.33 in Singapore and 0.0 in Alaska. Of studies reporting temporal occurrence, an increase in disease incidence was observed across North America and Northern Europe (4 studies), alongside an increase in prevalence over time (4 studies). The incidence and risks for clinical outcomes were presented by 9 of the included studies. Median transplant-free survival ranged from 9.7 (United States) to 20.6 years (Netherlands), with standardized mortality ratios of 2.5 and 4.2 compared with the control population. The standardized incidence of cholangiocarcinoma ranged from 235 (Finland) to 398 (Netherlands). CONCLUSIONS: Estimates of PSC incidence and prevalence vary, with most studies conducted in North America and Western Europe; the latter showing a steady increase in disease occurrence over time. Further research is needed to understand changes in disease epidemiology, including etiological drivers, the implications of rising case burden on health care policy, and better appreciation of PSC in the developing world.
引用
- Trivedi PJ, Bowlus CL, Yimam KK, et al. Epidemiology, Natural History, and Outcomes of Primary Sclerosing Cholangitis: A Systematic Review of Population-based Studies. Clin Gastroenterol Hepatol. 2021. PMID: 34474162. doi:10.1016/j.cgh.2021.08.039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。